Central Nervous System Therapeutics Market Will Surpass US$ 381.27 Billion at 10.5% CAGR Growth From 2025 to 2034

The growing existence of CNS disorders worldwide is a prominent factor driving the central nervous system therapeutics market.

NEW YORK CITY, NY, UNITED STATES, February 21, 2025 /EINPresswire.com/ -- 𝘛𝘩𝘦 𝘤𝘦𝘯𝘵𝘳𝘢𝘭 𝘯𝘦𝘳𝘷𝘰𝘶𝘴 𝘴𝘺𝘴𝘵𝘦𝘮 𝘵𝘩𝘦𝘳𝘢𝘱𝘦𝘶𝘵𝘪𝘤𝘴 𝘮𝘢𝘳𝘬𝘦𝘵 𝘧𝘰𝘳𝘦𝘤𝘢𝘴𝘵 𝘧𝘰𝘳 2034 𝘪𝘴 𝘢 𝘴𝘱𝘦𝘤𝘪𝘢𝘭𝘪𝘻𝘦𝘥 𝘴𝘵𝘶𝘥𝘺 𝘰𝘧 𝘵𝘩𝘦 𝘪𝘯𝘥𝘶𝘴𝘵𝘳𝘺 𝘸𝘪𝘵𝘩 𝘢 𝘴𝘱𝘦𝘤𝘪𝘧𝘪𝘤 𝘤𝘰𝘯𝘤𝘦𝘯𝘵𝘳𝘢𝘵𝘪𝘰𝘯 𝘰𝘯 𝘵𝘩𝘦 𝘨𝘭𝘰𝘣𝘢𝘭 𝘮𝘢𝘳𝘬𝘦𝘵 𝘵𝘳𝘦𝘯𝘥 𝘢𝘯𝘢𝘭𝘺𝘴𝘪𝘴.

𝐓𝐡𝐞 𝐜𝐞𝐧𝐭𝐫𝐚𝐥 𝐧𝐞𝐫𝐯𝐨𝐮𝐬 𝐬𝐲𝐬𝐭𝐞𝐦 𝐭𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐦𝐚𝐫𝐤𝐞𝐭 𝐢𝐬 𝐚𝐮𝐠𝐦𝐞𝐧𝐭𝐢𝐧𝐠. 𝐓𝐡𝐞 𝐦𝐚𝐫𝐤𝐞𝐭 𝐢𝐬 𝐚𝐩𝐩𝐫𝐨𝐱𝐢𝐦𝐚𝐭𝐞𝐝 𝐭𝐨 𝐫𝐞𝐚𝐜𝐡 𝐔𝐒𝐃 𝟑𝟖𝟏.𝟐𝟕 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 𝟐𝟎𝟑𝟒. 𝐈𝐭 𝐰𝐚𝐬 𝐯𝐚𝐥𝐮𝐞𝐝 𝐚𝐭 𝐔𝐒𝐃 𝟏𝟒𝟏.𝟎𝟗 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐢𝐧 𝟐𝟎𝟐𝟒. 𝐈𝐭 𝐞𝐱𝐡𝐢𝐛𝐢𝐭𝐞𝐝 𝐚 𝐂𝐀𝐆𝐑 𝐨𝐟 𝟏𝟎.𝟓% 𝐟𝐫𝐨𝐦 𝟐𝟎𝟐𝟓 𝐭𝐨 𝟐𝟎𝟑𝟒.

𝐖𝐡𝐚𝐭 𝐈𝐬 𝐂𝐞𝐧𝐭𝐫𝐚𝐥 𝐍𝐞𝐫𝐯𝐨𝐮𝐬 𝐒𝐲𝐬𝐭𝐞𝐦 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬?
Diagnosis of a nervous system disorder is time-consuming. Doctors work with patients to abolish several issues and render a particular diagnosis. They normally include several tests and an assessment of indications. Probable indications include persevering headaches and deprivation of tingling sensations.

𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐅𝐫𝐞𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐭𝐡𝐞 𝐑𝐞𝐩𝐨𝐫𝐭:
https://www.polarismarketresearch.com/industry-analysis/central-nervous-system-therapeutics-market/request-for-sample?utm_source=EIN&utm_medium=EIN&utm_campaign=EIN&utm_id=01

Treatment relies on particular conditions and may often include medicines and supplements, nutritional reinforcement, and spinal manipulation. Conditions such as depression, anxiety, Alzheimer’s disease, and multiple sclerosis are being detected more often, causing the growing demand for productive treatments and impacting the central nervous system therapeutics market growth favorably.

𝐖𝐡𝐨 𝐌𝐚𝐤𝐞𝐬 𝐂𝐞𝐧𝐭𝐫𝐚𝐥 𝐍𝐞𝐫𝐯𝐨𝐮𝐬 𝐒𝐲𝐬𝐭𝐞𝐦 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬?
The market is continuously developing with several firms struggling to invent and differentiate themselves. Here are some of the leading players in the central nervous system therapeutics market:
• Astra Zeneca
• Biogen
• Eli Lilly and Company
• Merck & Co., Inc.
• Novartis AG
• Otsuka Pharmaceutical Co., Ltd.
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd

𝐒𝐨𝐦𝐞 𝐨𝐟 𝐭𝐡𝐞 𝐥𝐚𝐭𝐞𝐬𝐭 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭𝐬 𝐢𝐧 𝐭𝐡𝐞 𝐦𝐚𝐫𝐤𝐞𝐭 𝐚𝐫𝐞:
• In May 2024, Teva Pharmaceuticals declared the FDA consent of AUSTEDO XR as a once-daily therapy for tardive dyskinesia and Huntington’s disease chorea, promoting four contemporary tablet robustness.

• In May 2024, an absolute global alternative and license agreement was declared between Takeda and AC Immune for the advancement of ACI-24.060, an agile immunotherapy aiming at toxic amyloid beta configurations that cures Alzheimer's disease and probably retarding its advancements.

𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐟𝐨𝐫 𝐚 𝐃𝐢𝐬𝐜𝐨𝐮𝐧𝐭 𝐨𝐧 𝐭𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 𝐁𝐞𝐟𝐨𝐫𝐞 𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞:
https://www.polarismarketresearch.com/industry-analysis/central-nervous-system-therapeutics-market/request-for-discount-pricing?utm_source=EIN&utm_medium=EIN&utm_campaign=EIN&utm_id=01

𝐖𝐡𝐚𝐭’𝐬 𝐃𝐫𝐢𝐯𝐢𝐧𝐠 𝐌𝐚𝐫𝐤𝐞𝐭 𝐅𝐨𝐫𝐰𝐚𝐫𝐝?
𝐒𝐭𝐫𝐨𝐧𝐠 𝐀𝐝𝐦𝐢𝐧𝐢𝐬𝐭𝐫𝐚𝐭𝐢𝐯𝐞 𝐑𝐞𝐢𝐧𝐟𝐨𝐫𝐜𝐞𝐦𝐞𝐧𝐭𝐬: The market demand is being propelled by robust administrative reinforcement for drug approvals. Administrative bodies such as the FDA have enhanced their procedures to ease speedier approvals for contemporary cures, especially for grave CNS disorders.

𝐆𝐫𝐨𝐰𝐢𝐧𝐠 𝐄𝐥𝐝𝐞𝐫𝐥𝐲 𝐏𝐨𝐩𝐮𝐥𝐚𝐭𝐢𝐨𝐧: Persons aged 50 and older are more vulnerable to neurological and mental health cases such as Alzheimer’s disease, dementia, and depression. For instance, in 2020, the Organization for Economic Co-operation and Development divulged that the allocation of the population aged 65 and above has surged to 17.96%. This, in turn, is having a favorable impact on central nervous system therapeutics market sales.

𝐒𝐮𝐫𝐠𝐢𝐧𝐠 𝐌𝐞𝐧𝐭𝐚𝐥 𝐇𝐞𝐚𝐥𝐭𝐡 𝐈𝐬𝐬𝐮𝐞𝐬: Growing consciousness of mental health problems is encouraging governments, establishments, and private investors to fund notably productive cures. For instance, as per the Keshav Desiraju India Mental Health Observatory, the Indian government administered USD 144.46 million in the yearly budget for 2023-2024 to confront mental health-connected illnesses.

𝐈𝐧𝐪𝐮𝐢𝐫𝐞 𝐦𝐨𝐫𝐞 𝐚𝐛𝐨𝐮𝐭 𝐭𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 𝐁𝐞𝐟𝐨𝐫𝐞 𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞:
https://www.polarismarketresearch.com/industry-analysis/central-nervous-system-therapeutics-market/inquire-before-buying?utm_source=EIN&utm_medium=EIN&utm_campaign=EIN&utm_id=01

𝐖𝐡𝐢𝐜𝐡 𝐑𝐞𝐠𝐢𝐨𝐧 𝐋𝐞𝐚𝐝𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐆𝐫𝐨𝐰𝐭𝐡?
𝐍𝐨𝐫𝐭𝐡 𝐀𝐦𝐞𝐫𝐢𝐜𝐚: North America accounted for the largest central nervous system therapeutics market share in 2024. The region’s robust growth is primarily due to the growing prevalence of Alzheimer’s disease.

𝐀𝐬𝐢𝐚 𝐏𝐚𝐜𝐢𝐟𝐢𝐜: Asia Pacific is anticipated to witness significant growth from 2025 to 2034. This can be attributed to growing government funding in healthcare.

𝐇𝐨𝐰 𝐈𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧 𝐃𝐨𝐧𝐞?
By Disease Outlook
• Neurovascular Diseases
• CNS Trauma
• Mental Health
• Neurodegenerative Diseases
• Alzheimer’s Disease
• Parkinson's Disease
• Multiple Sclerosis
• Huntington’s Disease
• Amyotrophic Lateral Sclerosis
• Others
• Infectious Diseases
• CNS Cancer
• Others

By Drug Class Outlook
• Anesthetics
• Anticonvulsants
• Antiemetics
• CNS Stimulants
• Pain Relievers
• Others

By Distribution Channel Outlook
• Hospital Pharmacies
• Retail Pharmacies
• Others

𝐁𝐲 𝐑𝐞𝐠𝐢𝐨𝐧𝐚𝐥 𝐎𝐮𝐭𝐥𝐨𝐨𝐤
• North America
o US
o Canada

• Europe
o Germany
o France
o UK
o Italy
o Spain
o Netherlands
o Russia
o Rest of Europe

• Asia Pacific
o China
o Japan
o India
o Malaysia
o South Korea
o Indonesia
o Australia
o Rest of Asia Pacific

• Middle East & Africa
o Saudi Arabia
o UAE
o Israel
o South Africa
o Rest of the Middle East & Africa

• Latin America
o Mexico
o Brazil
o Argentina
o Rest of Latin America

𝐅𝐀𝐐𝐬:
How much is the central nervous system therapeutics market?
The market size was valued at USD 141.09 billion in 2024 and is projected to grow to USD 381.27 billion by 2034.

Who are the key players in the central nervous system therapeutics market?
A few of the key players in the market are Biogen; Otsuka Pharmaceutical Co., Ltd.; Eli Lilly and Company; Merck & Co., Inc.; Astra Zeneca; Takeda
Pharmaceutical Company Limited; Novartis AG; Teva Pharmaceutical Industries Ltd; Johnson & Johnson, Inc.; and Pfizer Inc.

Based on drug class, which segment is expected to experience significant growth with a high CAGR in the global market?
The CNS stimulants segment is expected to experience significant growth with a high CAGR in the global market.

What are the segments covered in the market?
The segments covered in the market are disease, drug class, and distribution channel.

𝐁𝐫𝐨𝐰𝐬𝐞 𝐏𝐌𝐑'𝐬 𝐂𝐞𝐧𝐭𝐫𝐚𝐥 𝐍𝐞𝐫𝐯𝐨𝐮𝐬 𝐒𝐲𝐬𝐭𝐞𝐦 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐩𝐨𝐫𝐭 𝐂𝐨𝐯𝐞𝐫𝐚𝐠𝐞 𝐟𝐫𝐨𝐦 𝐃𝐢𝐟𝐟𝐞𝐫𝐞𝐧𝐭 𝐏𝐮𝐛𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧𝐬:
𝐂𝐞𝐧𝐭𝐫𝐚𝐥 𝐍𝐞𝐫𝐯𝐨𝐮𝐬 𝐒𝐲𝐬𝐭𝐞𝐦 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐬𝐢𝐳𝐞 𝐆𝐫𝐨𝐰𝐢𝐧𝐠 𝐭𝐨 $𝟑𝟖𝟏.𝟐𝟕 𝐁𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 𝟐𝟎𝟑𝟒 (𝟏𝟎.𝟓% 𝐂𝐀𝐆𝐑)

𝐁𝐫𝐨𝐰𝐬𝐞 𝐌𝐨𝐫𝐞 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐑𝐞𝐩𝐨𝐫𝐭𝐬:
Speaking Valve Market:
https://www.polarismarketresearch.com/industry-analysis/speaking-valve-market

Bio-Based Polypropylene in Medical Devices Market:
https://www.polarismarketresearch.com/industry-analysis/bio-based-polypropylene-in-medical-devices-market

3D Ultrasound Market:
https://www.polarismarketresearch.com/industry-analysis/3d-ultrasound-market

Sacral Nerve Stimulation Market:
https://www.polarismarketresearch.com/industry-analysis/sacral-nerve-stimulation-market

Central Nervous System Therapeutics Market:
https://www.polarismarketresearch.com/industry-analysis/central-nervous-system-therapeutics-market

Cholesterol Testing Products and Services Market:
https://www.polarismarketresearch.com/industry-analysis/cholesterol-testing-products-and-services-market

Vascular Stent Market:
https://www.polarismarketresearch.com/industry-analysis/vascular-stent-market

𝐀𝐛𝐨𝐮𝐭 𝐏𝐨𝐥𝐚𝐫𝐢𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 & 𝐂𝐨𝐧𝐬𝐮𝐥𝐭𝐢𝐧𝐠, 𝐈𝐧𝐜:
Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for PMR’s clientele spread across different enterprises. We at Polaris are obliged to serve PMR’s diverse customer base present across the industries of healthcare, technology, semiconductors, and chemicals among various other industries present around the world. We strive to provide PMR’s customers with updated information on innovative technologies, high-growth markets, emerging business environments, and the latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced, and extremely qualified team of experts comprising SMEs, analysts, and consultants, we at Polaris endeavor to deliver value-added business solutions to PMR’s customers.

Likhil G
Polaris Market Research and Consulting
+ +1 929-297-9727
email us here
Visit us on social media:
Facebook
X
LinkedIn